Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 6/20 | 0.36 |
| ▸ | METAP1 | P53582 | 5/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | NAAA | Q02083 | 2/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | CIT | O14578 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6747671 | 0.99 | CTSC (0.36) | CTSCMETAP2METAP1AAK1NAAA | |
| SCHEMBL6986613 | 0.77 | EPHX1 (0.33) | METAP2METAP1 | |
| SCHEMBL6753437 | 0.76 | CTSS (0.56) | CTSLCTSS | |
| SCHEMBL6749700 | 0.76 | CTSS (0.42) | METAP2METAP1CTSLCTSSLTA4H | |
| SCHEMBL6700232 | 0.75 | METAP2 (0.35) | CTSCMETAP2METAP1AAK1CTSL | |
| SCHEMBL7168993 | 0.73 | — | — | |
| SCHEMBL14347626 | 0.71 | NAAA (0.40) | CTSCMETAP2METAP1AAK1NAAA | |
| Hydrochloric Acid SCHEMBL5627174 | 0.70 | NAAA (0.39) | CTSCMETAP2METAP1AAK1NAAA | |
| Hydrochloric Acid SCHEMBL5627163 | 0.70 | NAAA (0.39) | CTSCMETAP2METAP1AAK1NAAA | |
| SCHEMBL6265800 | 0.68 | METAP2 (0.45) | CTSCMETAP2METAP1AAK1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | CTSC 77/4885METAP2 292/4885METAP1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.